A metabolomic approach to lung cancer

Suya Hori, Shin Nishiumi, Kazuyuki Kobayashi, Masakazu Shinohara, Yukihisa Hatakeyama, Yoshikazu Kotani, Naoya Hatano, Yoshimasa Maniwa, Wataru Nishio, Takeshi Bamba, Eiichiro Fukusaki, Takeshi Azuma, Tadaomi Takenawa, Yoshihiro Nishimura, Masaru Yoshida

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Lung cancer is one of the most common cancers in the world, but no good clinical markers that can be used to diagnose the disease at an early stage and predict its prognosis have been found. Therefore, the discovery of novel clinical markers is required. In this study, metabolomic analysis of lung cancer patients was performed using gas chromatography mass spectrometry. Serum samples from 29 healthy volunteers and 33 lung cancer patients with adenocarcinoma (n= 12), squamous cell carcinoma (n= 11), or small cell carcinoma (n= 10) ranging from stage I to stage IV disease and lung tissue samples from 7 lung cancer patients including the tumor tissue and its surrounding normal tissue were used. A total of 58 metabolites (57 individual metabolites) were detected in serum, and 71 metabolites were detected in the lung tissue. The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue. Partial least squares discriminant analysis, which is a form of multiple classification analysis, was performed using the serum sample data, and metabolites that had characteristic alterations in each histological subtype and disease stage were determined. Our results demonstrate that changes in metabolite pattern are useful for assessing the clinical characteristics of lung cancer. Our results will hopefully lead to the establishment of novel diagnostic tools.

Original languageEnglish
Pages (from-to)284-292
Number of pages9
JournalLung Cancer
Volume74
Issue number2
DOIs
Publication statusPublished - Nov 1 2011
Externally publishedYes

Fingerprint

Metabolomics
Lung Neoplasms
Serum
Healthy Volunteers
Biomarkers
Neoplasms
Small Cell Carcinoma
Discriminant Analysis
Least-Squares Analysis
Gas Chromatography-Mass Spectrometry
Lung Diseases
Squamous Cell Carcinoma
Adenocarcinoma
Lung

Keywords

  • Biomarker
  • GC/MS
  • Lung cancer
  • Metabolite
  • Metabolomics
  • PLS-DA

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Hori, S., Nishiumi, S., Kobayashi, K., Shinohara, M., Hatakeyama, Y., Kotani, Y., ... Yoshida, M. (2011). A metabolomic approach to lung cancer. Lung Cancer, 74(2), 284-292. https://doi.org/10.1016/j.lungcan.2011.02.008

A metabolomic approach to lung cancer. / Hori, Suya; Nishiumi, Shin; Kobayashi, Kazuyuki; Shinohara, Masakazu; Hatakeyama, Yukihisa; Kotani, Yoshikazu; Hatano, Naoya; Maniwa, Yoshimasa; Nishio, Wataru; Bamba, Takeshi; Fukusaki, Eiichiro; Azuma, Takeshi; Takenawa, Tadaomi; Nishimura, Yoshihiro; Yoshida, Masaru.

In: Lung Cancer, Vol. 74, No. 2, 01.11.2011, p. 284-292.

Research output: Contribution to journalArticle

Hori, S, Nishiumi, S, Kobayashi, K, Shinohara, M, Hatakeyama, Y, Kotani, Y, Hatano, N, Maniwa, Y, Nishio, W, Bamba, T, Fukusaki, E, Azuma, T, Takenawa, T, Nishimura, Y & Yoshida, M 2011, 'A metabolomic approach to lung cancer', Lung Cancer, vol. 74, no. 2, pp. 284-292. https://doi.org/10.1016/j.lungcan.2011.02.008
Hori S, Nishiumi S, Kobayashi K, Shinohara M, Hatakeyama Y, Kotani Y et al. A metabolomic approach to lung cancer. Lung Cancer. 2011 Nov 1;74(2):284-292. https://doi.org/10.1016/j.lungcan.2011.02.008
Hori, Suya ; Nishiumi, Shin ; Kobayashi, Kazuyuki ; Shinohara, Masakazu ; Hatakeyama, Yukihisa ; Kotani, Yoshikazu ; Hatano, Naoya ; Maniwa, Yoshimasa ; Nishio, Wataru ; Bamba, Takeshi ; Fukusaki, Eiichiro ; Azuma, Takeshi ; Takenawa, Tadaomi ; Nishimura, Yoshihiro ; Yoshida, Masaru. / A metabolomic approach to lung cancer. In: Lung Cancer. 2011 ; Vol. 74, No. 2. pp. 284-292.
@article{2830d9fc01764334bfa0e578a5af04f7,
title = "A metabolomic approach to lung cancer",
abstract = "Lung cancer is one of the most common cancers in the world, but no good clinical markers that can be used to diagnose the disease at an early stage and predict its prognosis have been found. Therefore, the discovery of novel clinical markers is required. In this study, metabolomic analysis of lung cancer patients was performed using gas chromatography mass spectrometry. Serum samples from 29 healthy volunteers and 33 lung cancer patients with adenocarcinoma (n= 12), squamous cell carcinoma (n= 11), or small cell carcinoma (n= 10) ranging from stage I to stage IV disease and lung tissue samples from 7 lung cancer patients including the tumor tissue and its surrounding normal tissue were used. A total of 58 metabolites (57 individual metabolites) were detected in serum, and 71 metabolites were detected in the lung tissue. The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue. Partial least squares discriminant analysis, which is a form of multiple classification analysis, was performed using the serum sample data, and metabolites that had characteristic alterations in each histological subtype and disease stage were determined. Our results demonstrate that changes in metabolite pattern are useful for assessing the clinical characteristics of lung cancer. Our results will hopefully lead to the establishment of novel diagnostic tools.",
keywords = "Biomarker, GC/MS, Lung cancer, Metabolite, Metabolomics, PLS-DA",
author = "Suya Hori and Shin Nishiumi and Kazuyuki Kobayashi and Masakazu Shinohara and Yukihisa Hatakeyama and Yoshikazu Kotani and Naoya Hatano and Yoshimasa Maniwa and Wataru Nishio and Takeshi Bamba and Eiichiro Fukusaki and Takeshi Azuma and Tadaomi Takenawa and Yoshihiro Nishimura and Masaru Yoshida",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.lungcan.2011.02.008",
language = "English",
volume = "74",
pages = "284--292",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A metabolomic approach to lung cancer

AU - Hori, Suya

AU - Nishiumi, Shin

AU - Kobayashi, Kazuyuki

AU - Shinohara, Masakazu

AU - Hatakeyama, Yukihisa

AU - Kotani, Yoshikazu

AU - Hatano, Naoya

AU - Maniwa, Yoshimasa

AU - Nishio, Wataru

AU - Bamba, Takeshi

AU - Fukusaki, Eiichiro

AU - Azuma, Takeshi

AU - Takenawa, Tadaomi

AU - Nishimura, Yoshihiro

AU - Yoshida, Masaru

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Lung cancer is one of the most common cancers in the world, but no good clinical markers that can be used to diagnose the disease at an early stage and predict its prognosis have been found. Therefore, the discovery of novel clinical markers is required. In this study, metabolomic analysis of lung cancer patients was performed using gas chromatography mass spectrometry. Serum samples from 29 healthy volunteers and 33 lung cancer patients with adenocarcinoma (n= 12), squamous cell carcinoma (n= 11), or small cell carcinoma (n= 10) ranging from stage I to stage IV disease and lung tissue samples from 7 lung cancer patients including the tumor tissue and its surrounding normal tissue were used. A total of 58 metabolites (57 individual metabolites) were detected in serum, and 71 metabolites were detected in the lung tissue. The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue. Partial least squares discriminant analysis, which is a form of multiple classification analysis, was performed using the serum sample data, and metabolites that had characteristic alterations in each histological subtype and disease stage were determined. Our results demonstrate that changes in metabolite pattern are useful for assessing the clinical characteristics of lung cancer. Our results will hopefully lead to the establishment of novel diagnostic tools.

AB - Lung cancer is one of the most common cancers in the world, but no good clinical markers that can be used to diagnose the disease at an early stage and predict its prognosis have been found. Therefore, the discovery of novel clinical markers is required. In this study, metabolomic analysis of lung cancer patients was performed using gas chromatography mass spectrometry. Serum samples from 29 healthy volunteers and 33 lung cancer patients with adenocarcinoma (n= 12), squamous cell carcinoma (n= 11), or small cell carcinoma (n= 10) ranging from stage I to stage IV disease and lung tissue samples from 7 lung cancer patients including the tumor tissue and its surrounding normal tissue were used. A total of 58 metabolites (57 individual metabolites) were detected in serum, and 71 metabolites were detected in the lung tissue. The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue. Partial least squares discriminant analysis, which is a form of multiple classification analysis, was performed using the serum sample data, and metabolites that had characteristic alterations in each histological subtype and disease stage were determined. Our results demonstrate that changes in metabolite pattern are useful for assessing the clinical characteristics of lung cancer. Our results will hopefully lead to the establishment of novel diagnostic tools.

KW - Biomarker

KW - GC/MS

KW - Lung cancer

KW - Metabolite

KW - Metabolomics

KW - PLS-DA

UR - http://www.scopus.com/inward/record.url?scp=80053654173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053654173&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.02.008

DO - 10.1016/j.lungcan.2011.02.008

M3 - Article

C2 - 21411176

AN - SCOPUS:80053654173

VL - 74

SP - 284

EP - 292

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -